Checkpoint Therapeutics (CKPT) Stock Price, News & Analysis

Company Overview

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology and targeted therapies for the treatment of solid tumors. Founded in 2016 and headquartered in San Mateo, California, the company is advancing a diversified pipeline of monoclonal antibodies and small-molecule inhibitors designed to address significant unmet needs in oncology. By leveraging insights into tumor immunology and molecular signaling pathways, Checkpoint Therapeutics aims to bring differentiated cancer therapies to patients across multiple indications.

The company’s lead candidate, cosibelimab, is a human anti–PD-L1 monoclonal antibody being evaluated in various solid tumors, including cutaneous squamous cell carcinoma, Merkel cell carcinoma and urothelial carcinoma. In tandem, Checkpoint is developing targeted therapies against the epidermal growth factor receptor (EGFR), notably its CK-101 and CK-301 programs, which are designed to overcome resistance mechanisms observed in patients with EGFR-driven cancers. These assets underscore Checkpoint’s strategy of combining immuno-oncology approaches with precision medicine to deliver enhanced clinical benefits.

Checkpoint Therapeutics operates in North America, Europe and select Asian markets, collaborating with academic institutions and industry partners to accelerate clinical development and regulatory review. The company’s management team, led by President and Chief Executive Officer Dennis Benjamin and Chief Medical Officer Dr. Adam M. Singer, brings extensive experience in oncology research, clinical development and regulatory affairs. This leadership has guided the company through successful financing rounds, an initial public offering in 2018 and multiple clinical milestones.

Looking ahead, Checkpoint Therapeutics continues to expand its clinical footprint, enrolling patients in late-stage trials while exploring strategic collaborations to broaden its commercial reach. With a clear focus on advancing therapies that harness the immune system and target key tumor drivers, the company remains committed to transforming the treatment landscape for patients with cancer around the world.

Key Stats

• Today's Range: $4.26 to $4.26
• 50-Day Range: $4.12 to $4.29
• 52-Week Range: $2.06 to $4.50
• Volume: N/A
• Average Volume: 1.51 million shs
• Market Capitalization: $370.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.33
• Consensus Rating: Hold

Checkpoint Therapeutics Stock Analysis - MarketRank™

Checkpoint Therapeutics scored higher than 11% of companies evaluated by MarketBeat, and ranked 888th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Checkpoint Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Checkpoint Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Checkpoint Therapeutics is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Checkpoint Therapeutics is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CKPT.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Checkpoint Therapeutics does not currently pay a dividend.

Dividend Growth

Checkpoint Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.63

Short Interest

There is no current short interest data available for CKPT.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.07

News Sentiment

Checkpoint Therapeutics has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Checkpoint Therapeutics this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for CKPT on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Checkpoint Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.10% of the stock of Checkpoint Therapeutics is held by insiders.

Percentage Held by Institutions

Only 22.00% of the stock of Checkpoint Therapeutics is held by institutions.

CKPT Stock Analysis - Frequently Asked Questions

How have CKPT shares performed this year?

Checkpoint Therapeutics' stock was trading at $3.20 at the start of the year. Since then, CKPT stock has increased by 33.1% and is now trading at $4.26.

How were Checkpoint Therapeutics' earnings last quarter?

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) released its earnings results on Tuesday, May, 13th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.09.

When did Checkpoint Therapeutics' stock split?

Checkpoint Therapeutics shares reverse split on the morning of Sunday, December 4th 2022.The 1-10 reverse split was announced on Sunday, December 4th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, December 4th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Checkpoint Therapeutics?

Shares of CKPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Checkpoint Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Checkpoint Therapeutics investors own include TG Therapeutics (TGTX), Bionano Genomics (BNGO), Fortress Biotech (FBIO), NIO (NIO), uniQure (QURE), VBI Vaccines (VBIV) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CKPT
• CIK: 1651407
• Web: www.checkpointtx.com
• Phone: (781) 652-4500
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Checkpoint Therapeutics: $4.33
• High Price Target: $4.80
• Low Price Target: $4.10
• Potential Upside/Downside: +1.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$51.85 million
• Net Margins: N/A
• Pretax Margin: -98,868.08%
• Return on Equity: N/A
• Return on Assets: -659.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.29
• Quick Ratio: 0.29

Sales & Book Value

• Annual Sales: $41 thousand
• Price / Sales: 9,041.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.47) per share
• Price / Book: -9.06

Miscellaneous

• Outstanding Shares: 87,020,000
• Free Float: 47,808,000
• Market Cap: $370.71 million
• Optionable: Optionable
• Beta: 1.18